中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
75
press releases in total
Year
-Year
2025
2024
2023
2022
2021
2020
2019
2018
2025
May 9, 2025
SHP2 Inhibitor Sitneprotafib Combination Therapy Data Published in Academic Journal
[More]
Mar 20, 2025
Jacobio Pharma Announces 2024 Annual Results
[More]
Jan 7, 2025
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine
[More]
2024
Dec 10, 2024
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
[More]
Nov 25, 2024
Jacobio Pharma Completes First Patient Dosage of Pan-KRAS Inhibitor
[More]
Oct 21, 2024
Glecirasib Pancreatic Cancer Indication Received Orphan Drug Designation from EMA
[More]
Oct 9, 2024
Jacobio Presents Pre-clinical Data of SHP2 plus KRAS G12C
[More]
Oct 3, 2024
Jacobio Pharma to Present BET Inhibitor Data at 2024 ASH
[More]
Sep 27, 2024
Jacobio Received RMB 172 million Payment
[More]
Sep 26, 2024
Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from China CDE
[More]
Sep 20, 2024
Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA
[More]
Sep 15, 2024
Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels
[More]
Aug 30, 2024
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
[More]
Aug 12, 2024
Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry
[More]
Aug 7, 2024
Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib
[More]
Jul 26, 2024
Jacobio Completes First Patient Dosage of p53 Y220C Activator
[More]
Jul 15, 2024
Jacobio Appoints Dr. Michael Ren as Vice President of Chemistry
[More]
Jun 13, 2024
Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology
[More]
Jun 2, 2024
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
[More]
May 21, 2024
Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib
[More]
Pages
1
2
3
4
›
»
京公网安备 11030102011242号